Analysts' optimism soars as they forecast Krystal Biotech to...
Analysts' optimism soars as they forecast Krystal Biotech to break even soon, given its massive projected annual growth rate of 68%. The firm's debt-free operation, unusual in loss-making biotech companies, lowers investment risk.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000001898a08f88208a.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment